Funding Round

Cognito Therapeutics Raises $105M Series C for Alzheimers Neurostimulation

BioSpace3/5/2026·03/05/26🌐 USA

Summary

Cognito Therapeutics raised $105M Series C for its non-invasive sensory-driven neurostimulation therapy platform for Alzheimers disease and other CNS disorders.

Why it matters

Cognito's $105M Series C funds the pivotal trial of their 40Hz gamma entrainment device for Alzheimer's, which uses light and sound stimulation rather than drugs or implants. Positive Phase 2 data showing slowed cognitive decline makes this one of the most closely watched non-pharmacological Alzheimer's programmes.

#Alzheimers#Industry#Neurostimulation#Venture Capital

Want the full NeurotechMag Pro intelligence database?

Access 800+ papers, trials, patents, funding rounds and news items — updated daily.

Start free trial

Already a member? Sign in